Citi has reiterated a 'sell' rating on Novo Nordisk, citing a slowdown in new prescriptions for its key GLP-1 obesity drugs, except oral Wegovy. Data up to August 21, 2026, shows significant declines in Rybelsus prescriptions and negative growth for Ozempic, while subcutaneous Wegovy shows some growth. Citi's analysis suggests potential double-digit upside for some drugs but overall pressure on the stock due to weakening new-patient trends. The sell rating implies around 9% further downside from recent prices.
Novo's drug CagriSema has demonstrated a significant 25% weight loss effect in women, a promising result that could boost the company's prospects. This development is important as it may help revive investor confidence and improve the company's stock...
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that develops software to assist biotech firms in managing drug discovery tasks such as finances and clinical trial scheduling. The acquisition aims to integrate Orchestra's techno...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Novo Nordisk's experimental obesity drug CagriSema demonstrated an average 25% weight loss among adult women after 68 weeks in a new analysis following a late-stage trial. The drug, combining semaglutide and cagrilintide, also showed significant weig...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
